ALT5 Sigma delays spinoff of Alyea Therapeutics unit

ALT5 Sigma Corporation (NASDAQ: ALTS) announced that a planned spinoff of its Alyea Therapeutics Corporation unit will not occur with the previously disclosed June 2, 2025, record date and may not proceed under the original timeline.

The company had disclosed in late 2024 a strategic plan to separate into two distinct companies and finance Alyea separately. The company cited "several factors" for the delay but did not specify the reasons.

ALT5 Sigma stated it will announce relevant information including a future record date, structure, and timing if it proceeds with a spinoff or similar transaction of Alyea at an appropriate time.

Alyea Therapeutics focuses on non-addictive pain treatment patents and potential clinical trials for its products. The company said it continues to evaluate strategic options to maximize and realize Alyea's value.

The information was disclosed in a company statement.

You May Also Be Interested In

• Cycurion projects $30M run-rate, drops reverse split plan
• HawkEye 360 Pathfinder satellite model added to Air and Space Museum
• Humacyte adds two nephrologists as advisors for dialysis product push